BA
AMRX icon

Boston Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Boston Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-36,570
Closed -$811K – 627
2018
Q3 		$811K Sell
36,570
-805
-2% -$16.9K 0.04% 412
2018
Q2 		$613K Buy
+37,375
New +$656K 0.02% 461

Other funds holding AMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Boston Advisors's AMRX Position: Q4 2018 in Review

Boston Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q4 2018, closing a stake of 36,570 shares — an estimated $811K sold.

Boston Advisors first reported a position in AMRX in Q2 2018 and held it in 2 quarters. The position peaked at $811K in Q3 2018. 168 funds tracked by Wall St. Rank hold AMRX as of Q4 2018.

  • Boston Advisors reported no remaining Amneal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Boston Advisors sold 36,570 Amneal Pharmaceuticals shares in Q4 2018, an estimated $811K.
  • Boston Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Boston Advisors's Amneal Pharmaceuticals position peaked at $811K in Q3 2018.
  • 168 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2018.

Based on Boston Advisors's 13F filing for Q4 2018, filed 16 Jan 2019.